Isomorphic Labs announced a $2.1 billion Series B financing led by Thrive Capital, describing it as a step-change in scaling its AI drug design engine, IsoDDE. The company framed the round as a “global vote of confidence” for an AI-first approach and said proceeds will support scaling, pipeline advancement, and hiring across engineering and clinical development. The round follows other large AI-biotech financings and further increases pressure on computational drug discovery groups to demonstrate translational outputs. Isomorphic also highlighted existing partnerships with major pharma players, positioning the funding to accelerate translation of model predictions into investigational assets. For investors and platform builders, the size and messaging underscore how rapidly AI drug design is moving from research to operational scale—though the company remained light on program-level specificity.